Onconetix, Inc. (ONCO)

Nasdaq: ONCO · Pharmaceutical Preparations · Cincinnati, OH · filing with the SEC since 2019

Full chart Alerts Compare

Grade3.3

◀ Past 2.8● Present 2.4▶ Future 4.5

2 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The companyfiscal 2025, as filed

Revenue$815,371-67.7%

Net income-$14.0M+76.1%

Earnings per share$-16.56+99.1%

Operating cash flow-$9.7M+7.8%

Cash$5.2M+707.5%

Debtn/a

Shareholders’ equity$15.8M+84.5%

Shares, diluted937,690+2803.0%

Return on equity-89.0%

The recordfrom its filings

Filings in 202665

Newest filingNov 12 · 8-K

Annual reportMar 13, 2026

Quarterly reportAug 13, 2026

Next report due10-Q by Nov 14

Insider sales, 12 months$0.00

Insider buys, 12 months$0.00

Patents granted1

Filer category<br>Emerging growth company

Trailing twelve months to Jun 2026Revenue $645,824Net income -$10.2MCash from operations -$10.3Mthe four newest filed quarters added

Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.

Revenue and net income by fiscal yearRevenueNet income

2122232425

As filed, in USD. Nothing here is a forecast.

News

Nov 12, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Nov 9, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Nov 6, 2026 · SEC EDGAR · Form 425

Merger communication

Open the filing on sec.gov

Nov 6, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Nov 5, 2026 · SEC EDGAR · Form SCHEDULE 13G/A

Large holder update, amended

Open the filing on sec.gov

Oct 27, 2026 · SEC EDGAR · Form 425

Merger communication

Open the filing on sec.gov

Oct 26, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Oct 23, 2026 · SEC EDGAR · Form DEFA14A

Extra proxy material

Open the filing on sec.gov

Oct 23, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Oct 23, 2026 · SEC EDGAR · Form 425

Merger communication

Open the filing on sec.gov

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.

SI brieffrom the record

Core business

Onconetix, Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Cincinnati, OH. Other Revenues was 72% of fiscal 2025 revenue.

Newest on the record

Current report on Nov 12. Before it, current report on Nov 9.

What is due next

The 10-Q for the period to Sep 30, 2026, due by Nov 14, 2026.

About ONCO

Onconetix, Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Cincinnati, OH. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $815 thousand and a loss of $14 million (its filed statements).

IndustryPharmaceutical Preparations

HeadquartersCincinnati, OH

Business modelPre-revenue company

ExchangeNasdaq

Filing since2019

Fiscal year endsDec 31

SEC number (CIK)1782107

Peers on fileHCWB, KPRX, RNTX, IMUX

Who runs it

Financial performance

In fiscal 2025 Onconetix’s revenue was $815,371, down 67.7% from $2.52 million the year before. It made a net loss of $14.03 million.

Annual report, filed Mar 13, 2026.

Financial statements

The grade

Onconetix grades 3.3 of 10 against its own industry, the 497 companies in Pharmaceutical Preparations. Seven of the nine metrics are read as filed and two are SI estimates, each with its reasoning.

◀ Past2.8

● Present2.4

▶ Future4.5

How the grade is made

Forecast

Every forecast is registered before the outcome, with the rule that settles it. A miss stays on the page.

Company forecasts

SI Assistanton ONCO · research, not advice